Ebola future or investigational therapies: Difference between revisions
Created page with "{{Ebola}} {{CMG}} {{MJM}} ==Overview== ==Future therapy== There is new research, that has been tested on monkeys, which shows some promising results as far as protection fr..." |
No edit summary |
||
| Line 7: | Line 7: | ||
==Future therapy== | ==Future therapy== | ||
There is new research, that has been tested on monkeys, which shows some promising results as far as protection from ebola. This new therapy has shown promise when it comes to treating accidental infections with the ebola virus, which would be a very important feat, especially for people working with ebola in laboratories{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=}}. The research, which took place under the supervision of the U.S. Army Medical Research Institute of Infectious Diseases, uses a specific group of compounds called antisense phosphorodiamidate morpholino oligomers, or PMOs{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=}}. The scientists eventually developed a therapy, which was referred to as AVI-6002, that was able to demonstrate a survival rate of approximately 90% in pre and post-exposure animals{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=}}. | There is new research, that has been tested on monkeys, which shows some promising results as far as protection from ebola. This new therapy has shown promise when it comes to treating accidental infections with the ebola virus, which would be a very important feat, especially for people working with ebola in laboratories<ref name="urlNovel antisense therapies protect primates from lethal Ebola and Marburg viruses">{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=2012-04-20}}</ref>. The research, which took place under the supervision of the U.S. Army Medical Research Institute of Infectious Diseases, uses a specific group of compounds called antisense phosphorodiamidate morpholino oligomers, or PMOs<ref name="urlNovel antisense therapies protect primates from lethal Ebola and Marburg viruses">{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=2012-04-20}}</ref>. The scientists eventually developed a therapy, which was referred to as AVI-6002, that was able to demonstrate a survival rate of approximately 90% in pre and post-exposure animals<ref name="urlNovel antisense therapies protect primates from lethal Ebola and Marburg viruses">{{cite web |url=http://www.sciencedaily.com/releases/2010/08/100822150645.htm |title=Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses |format= |work= |accessdate=2012-04-20}}</ref>. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
Revision as of 15:09, 20 April 2012
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Ebola future or investigational therapies |
|
Risk calculators and risk factors for Ebola future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.
Overview
Future therapy
There is new research, that has been tested on monkeys, which shows some promising results as far as protection from ebola. This new therapy has shown promise when it comes to treating accidental infections with the ebola virus, which would be a very important feat, especially for people working with ebola in laboratories[1]. The research, which took place under the supervision of the U.S. Army Medical Research Institute of Infectious Diseases, uses a specific group of compounds called antisense phosphorodiamidate morpholino oligomers, or PMOs[1]. The scientists eventually developed a therapy, which was referred to as AVI-6002, that was able to demonstrate a survival rate of approximately 90% in pre and post-exposure animals[1].
References
- ↑ 1.0 1.1 1.2 "Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses". Retrieved 2012-04-20.